Miguel-Angel Perales
Memorial Sloan Kettering Cancer Center
581 Papers
1.2K Citations
Miguel-Angel Perales is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 56, co-authored 379 publications. Previous affiliations of Miguel-Angel Perales include Tufts Medical Center & Cornell University.
Chat about Author
Papers
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
Steven J. Siegel,Susan DeWolf,Joseph T Schmalz,Wael Saber,Jiayi Dong,Michael J. Martens,Brent Logan,Alexandre Albanese,Lorenzo Iovino,Edward Chen,James Kaminski,D. Neuberg,Kyle Hebert,Paula Keskula,Jillian Zavistaski,Lea Steinberg,Isabella Schichter,Lorenzo Cagnin,Vanessa A Hernandez,Makya Warren,Kristy Applegate,Merav Bar,Saurabh Chhabra,Sung Choi,William Clark,Suman r Das,Robert R. Jenq,Richard J. Jones,John E. Levine,Hemant Murthy,Armin Rashidi,Marcie L. Riches,Karamjeet S. Sandhu,Anthony D. Sung,Karilyn Larkin,Monzr M. Al Malki,Mahasweta Gooptu,Hany Elmariah,Amin Alousi,Lyndsey Runaas,Brian C. Shaffer,Andrew R. Rezvani,Najla El Jurdi,Alison W Loren,Danielle Scheffey,Catherine Sanders,Mehdi Hamadani,Jarrod A Dudakov,Stephanie A Bien,Harlan Robins,Mary M. Horowitz,Javier Bolaños-Meade,Shernan G. Holtan,Ami S. Bhatt,Miguel-Angel Perales,Leslie S. Kean +55 more
Dynamics of Radiomic Features Following Bridging Therapy Determine CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome
H. Hubbeling,Doris Leithner,Emily A Silverman,Jessica R. Flynn,Sean M. Devlin,Gunjan L. Shah,Beatrice Fregonese,Akshay Bedmutha,Beatriz Wills,Ana Alarcon Tomas,Allison Parascondola,Amethyst Saldia,I. Landego,Parastoo B. Dahi,Sergio A. Giralt,Richard J. Lin,Michael Scordo,Gilles Salles,Joachim Yahalom,M. Lia Palomba,Heiko Schoder,Miguel-Angel Perales,Roni Shouval,Brandon S. Imber +23 more
TL;DR: The degree and dynamics of radiomic cytoreduction during the bridging period are prognostic and the MTV dynamics during BT were further prognostic with best PFS seen in the Low risk group (1yr PFS: 73%) and worst in the High risk groups and Rising risk groups.
Serious Infection Risk and Immune Recovery after Double-Unit Cord Blood Transplantation Without Antithymocyte Globulin
Craig S. Sauter,Craig S. Sauter,Michelle Abboud,Xiaoyu Jia,Glenn Heller,Anne-Marie Gonzales,Marissa Lubin,Rebecca Hawke,Miguel-Angel Perales,Miguel-Angel Perales,Marcel R.M. van den Brink,Marcel R.M. van den Brink,Sergio Giralt,Genovefa A. Papanicolaou,Genovefa A. Papanicolaou,Andromachi Scaradavou,Trudy N. Small,Trudy N. Small,Juliet N. Barker,Juliet N. Barker +19 more
TL;DR: The results suggest that double-unit CBT without ATG is associated with prompt T cell recovery, and, unlike in CBT incorporating ATG, infection is rarely a primary cause of death, and serious infections remain a challenge, especially in the setting of GVHD.
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation
Gunjan L. Shah,Gunjan L. Shah,Michael Scordo,Satyajit Kosuri,Satyajit Kosuri,Diego Adrianzen Herrera,Christina Cho,Sean M. Devlin,Taylor Borrill,Dean Carlow,Scott T. Avecilla,Richard Meagher,Richard J. O'Reilly,Richard J. O'Reilly,Ann A. Jakubowski,Ann A. Jakubowski,Esperanza B. Papadopoulos,Esperanza B. Papadopoulos,Guenther Koehne,Guenther Koehne,Boglarka Gyurkocza,Boglarka Gyurkocza,Hugo Castro-Malaspina,Hugo Castro-Malaspina,Brian C. Shaffer,Brian C. Shaffer,Miguel-Angel Perales,Miguel-Angel Perales,Sergio Giralt,Sergio Giralt,Roni Tamari,Roni Tamari +31 more
TL;DR: Overall, the toxicity of a more intense regimen is potentially balanced by the absence of toxicity related to methotrexate and calcineurin inhibitors in older patients.
Alternative donor transplantation for acute myeloid leukemia in patients aged ≥50 years: Young HLA-matched unrelated or haploidentical donor?
Miguel-Angel Perales,Benjamin Tomlinson,Mei-Jie Zhang,Andrew St. Martin,Amer Beitinjaneh,John Gibson,William J. Hogan,Natasha Kekre,Hillard M. Lazarus,David I. Marks,Joseph P. McGuirk,Rizwan Romee,Melhem Solh,John E. Wagner,Daniel J. Weisdorf,Marcos De Lima,Mary Eapen +16 more
TL;DR: The view that matched unrelated donor transplant with donors younger than 40 years is to be preferred is supported, as there was no difference in the risk of chronic graft-versus-host disease between donor types.